Abstract
The aim was to compare efficacy of treatments for diabetic macular oedema (DMO) from changes in visual acuity (VA) and central macular thickness (CMT). Peer-reviewed articles from 2004 to 2014 reporting intravitreal injections of bevacizumab (IVB), ranibizumab (IVR) or triamcinolone acetonide (IVTA) or laser photocoagulation therapy (LPT) provided data on pre-treatment (baseline) and final outcome measures. Net changes and relative changes (percentage) were assessed by linear regression analyses.
| Original language | English |
|---|---|
| Pages (from-to) | 491-497 |
| Number of pages | 7 |
| Journal | Clinical and Experimental Optometry |
| Volume | 99 |
| Issue number | 6 |
| Early online date | 19 Jun 2016 |
| DOIs | |
| Publication status | Published - Nov 2016 |
Keywords
- anti-VEGF treatments, corticosteroid treatments, diabetic macular oedema, laser photocoagulation
Fingerprint Dive into the research topics of 'On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review'. Together they form a unique fingerprint.
Cite this
Bong, A., Doughty, M., Button, N., & Mansfield, D. (2016). On the relationship between visual acuity and central retinal (macular) thickness after interventions for macular oedema in diabetics: a review. Clinical and Experimental Optometry, 99(6), 491-497. https://doi.org/10.1111/cxo.12393